

Europäisches
Patentamt

European Patent
Office

PCT/EP 2003/00104
Office européen
des brevets

16 DEC 2003



RECEIVED	
16 MAR 2004	
WIPO	PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten internationalen Patentanmeldung überein.

The attached documents are exact copies of the international patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet international spécifiée à la page suivante.

Den Haag; den
The Hague,
La Haye, le

08 MAR 2004

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1 (a) OR (b)

Der Präsident des Europäischen Patentamts
Im Auftrag
For the President of the European Patent Office
Le Président de l'Office européen des brevets
p. o.



C. v.d. Aa-Jansen

Patentanmeldung Nr. PCT/EP 02/14832
Patent application no.
Demande de brevet n°



Anmeldung Nr.:
Application no.:
Demande n°:

PCT/EP 02/14832

Anmelder:
Applicant(s):
Demandeur(s):

1. JANSSEN PHARMACEUTICA N.V. - Beerse, Belgium
2. LINDERS, Joannes, Theodorus, Maria - Beerse, Belgium (US only)
3. WILLEMSSENS, Gustaaf, Henri, Maria - Beerse, Belgium (US only)

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:

ADAMANTYL ACETAMIDES AS HYDROXYSTEROID
DEHYDROGENASE INHIBITORS

Anmeldetag:
Date of filing:
Date de dépôt:

23 December 2002 (23.12.2002)

In Anspruch genommene Priorität(en)
Priority(ies) claimed
Priorité(s) revendiquée(s)

Staat:
State:
Pays:

Tag:
Date:
Date:

Aktenzeichen:
File no.
Numéro de dépôt:

Benennung von Vertragsstaaten : Siehe Formblatt PCT/RO/101 (beigefügt)
Designation of contracting states : See Form PCT/RO/101 (enclosed)
Désignation d'états contractants : Voir Formulaire PCT/RO/101 (ci-joint)

Bemerkungen:
Remarks:
Remarques:

Further applicants:

4. GILISSEN, Ronaldus, Arnodus, Hendrika, Joseph - Beerse, Belgium (US only)
5. BUYCK, Christophe, Francis, Robert, Nestor - Beerse, Belgium (US only)
6. VANHOOF, Greta, Constantia, Peter - Beerse, Belgium (US only)
7. VAN DER VEKEN, Louis, Jozef, Elisabeth - Beerse, Belgium (US only)
8. JAROSKOVA, Libuse - Beerse, Belgium (US only)

PCT REQUEST

Original (for SUBMISSION) - printed on 20.12.2002 11:49:52 AM

PRD2023p

III-6	Applicant and/or inventor	
III-6-1	This person is:	applicant and inventor
III-6-2	Applicant for	US only
III-6-4	Name (LAST, First)	VAN DER VEKEN, Louis, Jozef, Elisabeth
III-6-5	Address:	Janssen Pharmaceutica N.V. Turnhoutseweg 30 B-2340 Beerse Belgium
III-6-6	State of nationality	BE
III-6-7	State of residence	BE
III-7	Applicant and/or inventor	
III-7-1	This person is:	applicant and inventor
III-7-2	Applicant for	US only
III-7-4	Name (LAST, First)	JAROSKOVA, Libuse
III-7-5	Address:	Janssen Pharmaceutica N.V. Turnhoutseweg 30 B-2340 Beerse Belgium
III-7-6	State of nationality	CZ
III-7-7	State of residence	BE
IV-1	Agent or common representative; or address for correspondence The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	common representative
IV-1-1	Name	JANSSEN PHARMACEUTICA N.V.
IV-1-2	Address:	Patent Department Turnhoutseweg 30 B-2340 Beerse Belgium
IV-1-3	Telephone No.	32+14 60 21 86
IV-1-4	Facsimile No.	32+14 60 54 91
IV-1-5	e-mail	patents@janbe.jnj.com
V	Designation of States	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	EP: AT BE BG CH&LI CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR and any other State which is a Contracting State of the European Patent Convention and of the PCT
V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	US
VI	Priority claim	NONE
VII-1	International Searching Authority Chosen	European Patent Office (EPO) (ISA/EP)

ADAMANTYL ACETAMIDES AS HYDROXYSTEROID DEHYDROGENASE INHIBITORS

5 The metabolic syndrome is a disease with increasing prevalence not only in the Western world but also in Asia and developing countries. It is characterised by obesity in particular central or visceral obesity, type 2 diabetes, hyperlipidemia, hypertension, arteriosclerosis, coronary heart diseases and eventually chronic renal failure (C.T. Montague et al. (2000), *Diabetes*, **49**, 883-888).

10 Glucocorticoids and 11β -HSD1 are known to be important factors in differentiation of adipose stromal cells into mature adipocytes. In the visceral stromal cells of obese patients, 11β -HSD1 mRNA level is increased compared with subcutaneous tissue. Further, adipose tissue over-expression of 11β -HSD1 in transgenic mice is associated with increased corticosterone levels in the adipose tissue, visceral obesity, insulin sensitivity, Type 2 diabetes, hyperlipidemia and hyperphagia (H. Masuzaki et al (2001), *Science*, **294**, 2166-2170). Therefore, 11β -HSD1 is most likely be involved in the development of visceral obesity and the metabolic syndrome.

15 Inhibition of 11β -HSD1 results in a decrease in differentiation and an increase in proliferation of adipose stromal cells. Moreover, glucocorticoid deficiency (adrenalectomy) enhances the ability of insulin and leptin to promote anorexia and weight loss, and this effect is reversed by glucocorticoid administration (P.M. Stewart et al (2002), *Trends Endocrin. Metabol*, **13**, 94-96). These data suggest that enhanced reactivation of cortisone by 11β -HSD1 may exacerbate obesity and it may be beneficial to inhibit this enzyme in adipose tissue of obese patients.

20 Obesity is also linked to cardiovascular risks. There is a significant relationship between cortisol excretion rate and HDL cholesterol in both men and women, suggesting that glucocorticoids regulate key components of cardiovascular risk. In analogy, aortic stiffness is also associated with visceral adiposity in older adults.

30 Glucocorticoids and glaucoma


Glucocorticoids increase the risk of glaucoma by raising the intraocular pressure when administered exogenously and in certain conditions of increased production like in Cushing's syndrome. Corticosteroid-induced elevation of intra ocular pressure is caused by increased resistance to aqueous outflow due to glucocorticoid induced changes in the trabecular meshwork and its intracellular matrix. Zhou et al. (*Int J Mol*

Med (1998) 1, 339-346) also reported that corticosteroids increase the amounts of fibronectin as well as collagen type I and type IV in the trabecular meshwork of organ-cultured bovine anterior segments.

11 β -HSD1 is expressed in the basal cells of the corneal epithelium and the non-pigmented epithelial cells. Glucocorticoid receptor mRNA was only detected in the trabecular meshwork, whereas in the non-pigmented epithelial cells mRNA for the glucocorticoid-, mineralocorticoid receptor and 11 β -HSD1 was present. Carbenoxolone administration to patients resulted in a significant decrease in intra-ocular pressure (S. Rauz et al. (2001), Invest. Ophthalmol. Vis. Science, 42, 2037-2042), suggesting a role for HSD1-inhibitors in treating glaucoma.

Accordingly, the underlying problem to be solved by the present invention was to identify potent 11 β -HSD inhibitors, with a high selectivity for 11 β -HSD1, and the use thereof in treating pathologies associated with excess cortisol formation such as obesity, diabetes, obesity related cardiovascular diseases, and glaucoma.

This invention concerns compounds of formula (I)



the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein


n represents an integer being 0, 1 or 2;

m represents an integer being 0 or 1;

R^1 and R^2 each independently represents hydrogen, C_{1-4} alkyl, NR^9R^{10} , C_{1-4} alkyloxy, $\text{Het}^3\text{-O-C}_{1-4}$ alkyl; or

R^1 and R^2 taken together with the carbon atom with which they are attached form a carbonyl, or a C_{3-6} cycloalkyl; and where *n* is 2, either R^1 or R^2 may be absent to form an unsaturated bond;

R^3 represents hydrogen, Ar^1 , C_{1-8} alkyl, C_{6-12} cycloalkyl or a monovalent radical having one of the following formulae



wherein said Ar^1 , C_{6-12} cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two or three substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkyloxy, phenyl, halo, oxo, carbonyl, 1,3-dioxolyl or hydroxy;

R^4 represents hydrogen or C_{1-4} alkyl;

Q represents C_{3-8} cycloalkyl, Het^1 or Ar^2 , wherein said C_{3-8} cycloalkyl, Het^1 or Ar^2 are optionally substituted with one or where possible more substituents selected from halo, C_{1-4} alkyl, C_{1-4} alkyloxy, hydroxy, nitro, Het^4 , phenyl, phenyloxy, C_{1-4} alkyloxycarbonyl, hydroxycarbonyl, NR^5R^6 , C_{1-4} alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het^2 and NR^7R^8 , and

C_{1-4} alkyl substituted with one or where possible two or three halo substituents;

R^5 and R^6 are each independently selected from hydrogen, C_{1-4} alkyl, C_{1-4} alkyloxy, C_{1-4} alkyl, C_{1-4} alkyloxycarbonyl, C_{1-4} alkylcarbonyl, C_{1-4} alkylcarbonyl substituted with one or where possible two or three substituents each independently selected from halo, C_{1-4} alkyl, and C_{1-4} alkyloxy or R^5 and R^6 each independently represent C_{1-4} alkyl substituted with phenyl;

R^7 and R^8 are each independently selected from hydrogen or C_{1-4} alkyl;

R^9 and R^{10} are each independently selected from hydrogen, C_{1-4} alkyl or C_{1-4} alkyloxycarbonyl;

L represents C_{1-4} alkyl optionally substituted with one or where possible more substituents selected from C_{1-4} alkyl or phenyl;

Het^1 represents a heterocycle selected from pyridinyl, piperidinyl, pyrimidinyl, pyrazinyl, piperazinyl, pyridazinyl, indolyl, isoindolyl, indolinyl, furanyl, benzofuranyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, benzothienyl,

thiophenyl, 1,8-naphthyridinyl, 1,6-naphthyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, phthalazinyl, or 1,3-benzodioxolyl.;

Het² represents a monocyclic heterocycle selected from piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 2H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, or morpholinyl;

Het³ represents a monocyclic heterocycle selected from 2H-pyranyl, 4H-pyranyl, furanyl, tetrahydro-2H-pyranyl, pyridinyl, piperidinyl, or furanyl;

Het⁴ represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het⁴ optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy;

Ar¹ represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, biphenyl, indenyl, 2,3-dihydroindenyl, fluorenyl, 5,6,7,8-tetrahydronaphtyl or naphtyl

Ar² represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, biphenyl, indenyl, 2,3-dihydroindenyl, fluorenyl, 5,6,7,8-tetrahydronaphtyl or naphtyl.

As used in the foregoing definitions and hereinafter, halo is generic to fluoro, chloro, bromo and iodo; C₁₋₄alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-methylethyl, 2-methylpropyl, 2,2-dimethylethyl and the like; C₁₋₈alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 8 carbon atoms such as the groups defined for C₍₁₋₄₎alkyl and pentyl, hexyl, octyl, 2-methylbutyl, 2-methylpentyl, 2,2-dimethylpentyl and the like; C₃₋₆cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; C₆₋₁₂cycloalkyl is generic to cycloheptyl and cyclo-octanyl, cyclononane, cyclodecane, cycloundecane and cyclododecane; C₁₋₄alkyloxy defines straight or branched saturated hydrocarbon radicals such as methoxy, ethoxy, propyloxy, butyloxy, 1-methylethyloxy, 2-methylpropyloxy and the like.

As used herein before, the terms oxo or carbonyl refers to (=O) that forms a carbonyl moiety with the carbon atom to which it is attached.

The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms, which the compounds of formula (I), are able to form. The latter can conveniently be obtained by

treating the base form with such appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic and the like acids.

The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic base addition salt forms which the compounds of formula (I), are able to form. Examples of such base addition salt forms are, for example, the sodium, potassium, calcium salts, and also the salts with pharmaceutically acceptable amines such as, for example, ammonia, alkylamines, benzathine, *N*-methyl-*D*-glucamine, hydrabamine, amino acids, e.g. arginine, lysine.

Conversely said salt forms can be converted by treatment with an appropriate base or acid into the free acid or base form.


The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I), as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.

The term stereochemically isomeric forms as used hereinbefore defines the possible different isomeric as well as conformational forms which the compounds of formula (I), may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically and conformationally isomeric forms, said mixtures containing all diastereomers, enantiomers and/or conformers of the basic molecular structure. All stereochemically isomeric forms of the compounds of formula (I), both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.

The *N*-oxide forms of the compounds of formula (I), are meant to comprise those compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called *N*-oxide.

An interesting group of compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply :

- (i) n represents an integer being 1 or 2 provided that when n represents 2, Q represents Het¹ or Ar², wherein said Het¹ or Ar² are optionally substituted with one or where possible more substituents selected from halo, C₁₋₄alkyl, C₁₋₄alkyloxy, hydroxy, nitro, Het⁴, phenyl, phenyloxy, hydroxycarbonyl, NR⁵R⁶, C₁₋₄alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het² and NR⁷R⁸, and C₁₋₄alkyl substituted with one or where possible two or three halo substituents;
- (ii) R¹ and R² each independently represents hydrogen, C₁₋₄alkyl, NR⁹R¹⁰, C₁₋₄alkyloxy, Het³-O-C₁₋₄alkyl; or R¹ and R² taken together with the carbon atom with which they are attached form a carbonyl, or a C₃₋₆cycloalkyl;
- (iii) R³ represents phenyl, C₆₋₁₂cycloalkyl or a monovalent radical having one of the following formulae



- wherein said phenyl, C₆₋₁₂cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two or three substituents selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkyloxy, halo, carbonyl, phenyl or hydroxy;
- (iv) R⁴ represents hydrogen or C₁₋₄alkyl;
- (v) Q represents Het¹ or Ar², wherein said Het¹ or Ar² are optionally substituted with one or where possible more substituents selected from halo, C₁₋₄alkyl, C₁₋₄alkyloxy, hydroxy, nitro, Het⁴, phenyl, phenyloxy, hydroxycarbonyl, NR⁵R⁶, C₁₋₄alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het² and NR⁷R⁸, and C₁₋₄alkyl substituted with one or where possible two or three halo substituents;
- (vi) Het¹ represents a heterocycle selected from piperinidyl, pyrimidinyl, pyrazinyl, piperazinyl, pyridazinyl, indolyl, isoindolyl, indolinyl, benzofuranyl,


benzothiophenyl, 1,8-naphthyridinyl, 1,6-naphthyridinyl, quinazolinyl, phthalazinyl, or 1,3-benzodioxolyl;

(vii) Ar^2 represents phenyl or naphthyl optionally substituted with C_{1-4} alkyl, C_{1-4} alkyloxy or halo; preferably substituted with methyl or methoxy.

5

Another interesting group of compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply :

- (i) R^1 and R^2 each independently represents hydrogen C_{1-4} alkyl, NR^9R^{10} ; or R^1 and R^2 taken together with the carbon atom with which they are attached form a C_{3-6} cycloalkyl; and where n is 2, either R^1 or R^2 may be absent to form an unsaturated bond;
- 10 (ii) R^3 represents a C_{6-12} cycloalkyl or a monovalent radical having one of the following formulae



15


wherein said C_{6-12} cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkyloxy, halo, carbonyl, hydroxy, or 1,3-dioxolyl;

- (iii) Q represents Het^1 or Ar^2 wherein said Het^1 or Ar^2 are optionally substituted with one or where possible two or more substituents selected from halo, C_{1-4} alkyl, C_{1-4} alkyloxy, hydroxy, C_{1-4} alkyloxycarbonyl, NR^5R^6 , C_{1-4} alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het^2 and NR^7R^8 , and C_{1-4} alkyl substituted with one or where possible two or three halo substituents;
- 20 (iv) R^5 and R^6 are each independently selected from hydrogen, C_{1-4} alkyl, C_{1-4} alkylcarbonyl, C_{1-4} alkylcarbonyl substituted with one or where possible two or three halo substituents.
- 25

- (v) R^9 and R^{10} are each independently selected from hydrogen or C_{1-4} alkyl;
- (vi) L represents a C_{1-4} alkyl, preferably methyl;
- (vii) Het^1 represents a heterocycle selected from pyridinyl, pyrimidinyl, thiophenyl or 1,3-benzodioxolyl;
- 5 (viii) Het^2 represents a monocyclic heterocycle selected from piperidinyl, pyridinyl, pyrrolidinyl or morpholinyl;
- (ix) Ar^2 represents a C_{6-14} aryl preferably selected from phenyl, naphthyl or indenyl.

10 A particular group of compounds of formula (I) were those compounds shown to be highly HSD1 specific. For these compounds of formula (I) one or more of the following restrictions apply :

- (i) n represents an integer being 1 or 2;
- (ii) R^1 and R^2 each independently represents hydrogen C_{1-4} alkyl, NR^9R^{10} ; or R^1 and R^2 taken together with the carbon atom with which they are attached form a C_{3-6} cycloalkyl; and where n is 2, either R^1 or R^2 may be absent to form an unsaturated bond;
- 15 (iii) R^3 represents a C_{6-12} cycloalkyl, preferably cylo-octanyl or a monovalent radical having one of the following formulae



- 20 wherein said C_{6-12} cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkyloxy, halo or hydroxy;
- (iv) Q represents Het^1 or Ar^2 wherein said Het^1 or Ar^2 are optionally substituted with one or where possible two or more substituents selected from halo, C_{1-4} alkyl, C_{1-4} alkyloxy, hydroxy, NR^5R^6 , C_{1-4} alkyloxy substituted with one or
 - 25 where possible two, three or more substituents each independently selected from


hydroxycarbonyl, Het² and NR⁷R⁸, and C₁₋₄alkyl substituted with one or where possible two or three halo substituents;

- (v) R⁵ and R⁶ each independently represent hydrogen or C₁₋₄alkyl;
- (vi) R⁹ and R¹⁰ each independently represent hydrogen or C₁₋₄alkyloxycarbonyl;
- 5 (vii) L represents C₁₋₄alkyl;
- (viii) Het¹ represents a heterocycle selected from pyridinyl, piperidinyl, thiophenyl or 1,3-benzodioxol;
- (ix) Het² represents pyridinyl, pyrrolidinyl or morpholinyl;
- (x) Ar² represents phenyl, naphthyl or indenyl.

10

A subgroup of these highly HSD1 specific inhibitors was shown to have a superior cellular activity and consist of compounds of formulae (I) wherein one or more of the following restrictions apply

- (i) n represents an integer being 1 or 2;
- 15 (ii) R¹ and R² each independently represents hydrogen, C₁₋₄alkyl; or R¹ and R² taken together with the carbon atom with which they are attached form a C₃₋₆cycloalkyl; and where n is 2, either R¹ or R² may be absent to form an unsaturated bond;
- (iii) R³ represents a C₆₋₁₂cycloalkyl, preferably cyclo-octanyl or a monovalent radical
- 20 having one of the following formulae




wherein said C₆₋₁₂cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkyloxy, halo or hydroxy;

- 25 (iv) Q represents Het¹ or Ar² wherein said Het¹ or Ar² are optionally substituted with one or where possible two or more substituents selected from halo, C₁₋₄alkyl, C₁₋₄alkyloxy, hydroxy, NR⁵R⁶, C₁₋₄alkyloxy substituted with one or where possible two, three or more substituents each independently selected from hydroxycarbonyl, Het² and NR⁷R⁸, and C₁₋₄alkyl substituted with one or where possible two or three halo substituents;
- 30

- (v) R^5 and R^6 each independently represent hydrogen or C_{1-4} alkyl;
- (vi) L represents C_{1-4} alkyl;
- (vii) Het^1 represents a heterocycle selected from pyridinyl, piperidinyl, thiophenyl or 1,3-benzodioxol;
- 5 (viii) Het^2 represents pyrrolidinyl or morpholinyl;
- (ix) Ar^2 represents phenyl, naphthyl or indenyl.

Further interesting compounds according to the invention are those compounds of formulae (I) wherein one or more of the following restrictions apply

- 10 (i) n represents an integer being 1 or 2;
- (ii) R^1 and R^2 each independently represents hydrogen C_{1-4} alkyl, NR^9R^{10} , C_{1-4} alkyloxy; or
 R^1 and R^2 taken together with the carbon atom with which they are attached form a C_{3-6} cycloalkyl; and where n is 2, either R^1 or R^2 may be absent to form an unsaturated bond;
- 15 (iii) R^3 represents a C_{6-12} cycloalkyl, preferably selected from cylo-octanyl and cyclohexyl or R^3 represents a monovalent radical having one of the following formulae




- 20 wherein said C_{6-12} cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkyloxy, halo or hydroxy;
- (iv) Q represents C_{3-8} cycloalkyl, Het^1 or Ar^2 wherein said C_{3-8} cycloalkyl, Het^1 or Ar^2 are optionally substituted with one or where possible two or more substituents selected from halo, C_{1-4} alkyl, C_{1-4} alkyloxy, hydroxy, nitro, NR^5R^6 , C_{1-4} alkyloxy substituted with one or where possible two, three or more substituents each independently selected from hydroxycarbonyl, Het^2 and NR^7R^8 , and C_{1-4} alkyl substituted with one or where possible two or three halo substituents, preferably trifluoromethyl;
- 25

- (v) R^5 and R^6 each independently represent hydrogen, C_{1-4} alkyl, or C_{1-4} alkyl substituted with phenyl;
- (vi) L represents C_{1-4} alkyl;
- (vii) Het^1 represents a heterocycle selected from pyridinyl, piperidinyl, or thiophenyl;
- 5 (viii) Het^2 represents piperidinyl, pyrrolidinyl or morpholinyl;
- (ix) Ar^2 represents phenyl, naphthyl or indenyl.

A particular group of compounds of formula (I) are those where one or more of the following restrictions apply :

- 10 (i) n represents an integer being 1 or 2;
- (ii) R^1 and R^2 each independently represents hydrogen C_{1-4} alkyl, NR^9R^{10} , C_{1-4} alkyloxy; or
 R^1 and R^2 taken together with the carbon atom with which they are attached form a C_{3-6} cycloalkyl; and where n is 2, either R^1 or R^2 may be absent to form an unsaturated bond;
- 15 (iii) R^3 represents a C_{6-12} cycloalkyl, preferably selected from cyclo-octanyl and cyclohexyl or R^3 represents a monovalent radical having one of the following formulae



- 20 wherein said C_{6-12} cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkyloxy, halo or hydroxy;
- (iv) Q represents Het^1 or Ar^2 wherein said C_{3-8} cycloalkyl, Het^1 or Ar^2 are optionally substituted with one or where possible two or more substituents selected from
- 25 halo, C_{1-4} alkyl, C_{1-4} alkyloxy, hydroxy, nitro, NR^5R^6 , C_{1-4} alkyloxy substituted with one or where possible two, three or more substituents each independently selected from hydroxycarbonyl, Het^2 and NR^7R^8 , and C_{1-4} alkyl substituted with one or where possible two or three halo substituents, preferably trifluoromethyl;
- (v) R^5 and R^6 each independently represent hydrogen, C_{1-4} alkyl, or C_{1-4} alkyl substituted with phenyl;
- 30 (vi) L represents C_{1-4} alkyl;

- (vii) Het¹ represents a heterocycle selected from pyridinyl, thiophenyl, or 1,3-benzodioxolyl;
- (viii) Het² represents piperidinyl, pyrrolidinyl or morpholinyl;
- (ix) Ar² represents phenyl, naphthyl or indenyl.


5

A preferred group of compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply :

- (i) Q represents phenyl, said phenyl optionally substituted with one or two substituents selected from the halo, preferably chloro or fluor, or C₁₋₄alkyloxy preferably methoxy. ;
- (ii) n is 1;
- (iii) m is 0;
- (iv) R¹ and R² represent C₁₋₄alkyl, preferably methyl; or
R¹ and R² taken together with the carbon atom with which they are attached form a C₃₋₆cycloalkyl, preferably cyclopropyl;
- (v) R⁴ represents hydrogen;
- (vi) R³ represents a monovalent radical having one of the following formulae

10


15



- wherein said monovalent radical may optionally be substituted with one or where possible two or three substituents selected from halo, carbonyl, hydroxy or C₁₋₄alkyloxy, preferably methoxy.

- Also of interest are those compounds of formula (I) wherein the R³ substituent is being selected from the monovalent radicals having one of the following formulae

25




optionally substituted with one, or where possible two or three substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkyloxy, phenyl, halo, oxo, carbonyl, 1,3-dioxolyl or hydroxy; even more preferably those compounds wherein the R^3 substituent is 2-adamantyl optionally substituted with one, or where possible two or three substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkyloxy, halo, oxo, carbonyl or hydroxy.

- 10 The amide compounds of this invention can be prepared by any of several standard synthetic processes commonly used by those skilled in the art of organic chemistry and described for instance in; "Introduction to organic chemistry" Streitweiser and Heathcock – Macmillan Publishing Co., Inc. – second edition - New York – Section 24.7 (partA) p 753-756. In general, the amides can be prepared through a base-
- 15 catalyzed nucleophilic addition between the appropriate carboxylic acid with the corresponding amine (scheme 1), or via a nucleophilic substitution reaction wherein the appropriate amine reacts with either the corresponding acyl halide (scheme 2), anhydride or ester, to yield the required amide.
- 20 When coupling the acids to the amines, standard chemical coupling reagents such as carbonyldiimidazole (CDI), 1,3-dicyclohexylcarbodiimide (DCC) or 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) are used in the presence or absence of hydroxybenzotriazole (HOBt). In general, adding of the carboxylic acids of formula (III) to the amines of formula (II) under base-catalyzed reaction conditions
- 25 results in the formation of the amine salt which is in equilibrium with its weak acid and base. To force the equilibrium to the formation of the amide of formula (I), a


dehydrogenating agent such as carbodiimides, for example DCC and CDI are added to the reaction mixture.

Scheme 1



In an alternative embodiment the carboxylic acids or converted into the corresponding acyl halides by reaction with, for example, thionyl chloride or oxalyl chloride. Subsequently said acyl halide (V) is added to the amine of formula (II) to yield the amide of formula (I) using art known reaction procedures such as the Schotten-Baumann method.


Scheme 2



The carboxylic acids of formula (III) and the amines of formula (II) are readily available, or may be prepared using methods that are well known in the art. Many compounds are commercially available, for example, from Aldrich Chemicals, or when the compounds are not commercially available, they may be readily prepared from available precursors using straightforward transformations that are well known in the art.


- For example the carboxylic acids are most often prepared by hydrolysis of nitriles (scheme 3), carbonation of organometallic compounds or oxidation of primary alcohols or aldehydes, see for instance in; "Introduction to organic chemistry" Streitweiser and Heathcock – Macmillan Publishing Co., Inc. – second edition - New York – Section 19.6 p 509-511. In particular the carboxylic acids of formula (III) are prepared from the corresponding (hetero)aryl acetonitriles (VI) by conversion to the dialkyl or spiroalkyl derivative (VII) using e.g., sodium hexamethyldisilazane and methyl iodide or dibromobutane (see e.g., Trivedi et al, J. Med. Chem. **1993**, 36, 3300), followed by hydrolysis under acidic or basic conditions to the desired carboxylic acid III.
- Appropriate acids and bases in the hydrolysis are for example H_2SO_4 and KOH . The hydrolysis reaction can be conveniently performed using microwave heating.

Scheme 3



- The amines of formula (II) are generally prepared using art known techniques, see for instance in; "Introduction to organic chemistry" Streitweiser and Heathcock – Macmillan Publishing Co., Inc. – second edition - New York – Section 24.6 p 742-753, and comprise synthesis through indirect alkylation of the appropriate (hetero)aryl halides in particular by the Gabriel synthesis, through reduction of the corresponding nitro or nitrile compounds, through reductive amination using for example the Eschweiler-Clarke reaction and in particular through the reduction of oximes (IX) which may be prepared from aldehydes or ketones (VIII) by reaction with hydroxylamine (scheme 4). In this latter case the oximes are reduced by lithium aluminium hydride or catalytic hydrogenation using an appropriate catalyst such as Rainey Nickel, said reduction being performed in an inert anhydrous solvent such as ether or tetrahydrofuran (THF).

Scheme 4



Further examples for the synthesis of compounds of formula (I) using anyone of the above mentioned synthesis methods, are provided in the experimental part hereinafter.

Where necessary or desired, any one or more of the following further steps in any order may be performed :

- (i) removing any remaining protecting group(s);
- (ii) converting a compound of formula (I) or a protected form thereof into a further compound of formula (I) or a protected form thereof;
- (iii) converting a compound of formula (I) or a protected form thereof into a *N*-oxide, a salt, a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof;
- (iv) converting a *N*-oxide, a salt, a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof into a compound of formula (I) or a protected form thereof;
- (v) converting a *N*-oxide, a salt, a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof into another *N*-oxide, a pharmaceutically acceptable addition salt a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof;
- (vi) where the compound of formula (I) is obtained as a mixture of (R) and (S) enantiomers resolving the mixture to obtain the desired enantiomer.

Compounds of formula (I), *N*-oxides, addition salts, quaternary amines and stereochemical isomeric forms thereof can be converted into further compounds according to the invention using procedures known in the art, for example :

It will be appreciated by those skilled in the art that in the processes described above the functional groups of intermediate compounds may need to be blocked by protecting groups.

Functional groups which it is desirable to protect include hydroxy, amino and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl groups (e.g. tert-butyldimethylsilyl, tert-butyldiphenylsilyl or trimethylsilyl), benzyl and tetrahydropyranyl. Suitable protecting groups for amino include tert-butoxycarbonyl or benzyloxycarbonyl. Suitable protecting groups for carboxylic acid include C₍₁₋₆₎alkyl or benzyl esters.

The protection and deprotection of functional groups may take place before or after a reaction step.

10

The use of protecting groups is fully described in 'Protective Groups in Organic Chemistry', edited by J W F McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis' 2nd edition, T W Greene & P G M Wutz, Wiley Interscience (1991).

15 Additionally, the N-atoms in compounds of formula (I) can be methylated by art-known methods using CH₃-I in a suitable solvent such as, for example 2-propanone, tetrahydrofuran or dimethylformamide.

20 The compounds of formula (I), can also be converted into each other following art-known procedures of functional group transformation of which some examples are mentioned hereinabove.

25 The compounds of formula (I), may also be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with 3-phenyl-2-(phenylsulfonyl)oxaziridine or with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid, peroxyalkanoic acids, e.g. peroxyacetic acid, alkylhydroperoxides, e.g. *t*-butyl hydroperoxide. Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

35

Pure stereochemically isomeric forms of the compounds of formula (I), may be obtained by the application of art-known procedures. Diastereomers may be separated

by physical methods such as selective crystallization and chromatographic techniques, e.g. counter-current distribution, liquid chromatography and the like.

5 Some of the compounds of formula (I), and some of the intermediates in the present invention may contain an asymmetric carbon atom. Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, liquid chromatography and the like methods. Enantiomers can be
10 obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated
15 diastereomeric salts or compounds into the corresponding enantiomers. Pure stereochemically isomeric forms may also be obtained from the pure stereochemically isomeric forms of the appropriate intermediates and starting materials, provided that the intervening reactions occur stereospecifically.

20 . An alternative manner of separating the enantiomeric forms of the compounds of formula (I) and intermediates involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase.

25 Some of the intermediates and starting materials as used in the reaction procedures mentioned hereinabove are known compounds and may be commercially available or may be prepared according to art-known procedures.

30 The compounds of the present invention are useful because they possess pharmacological properties. They can therefore be used as medicines, in particular to treat pathologies associated with excess cortisol formation such as for example, obesity, diabetes, obesity related cardiovascular diseases, and glaucoma.

35 As described in the experimental part hereinafter, the inhibitory effect of the present compounds on the 11b-HSD1-reductase activity (conversion of cortison into cortisol) has been demonstrated *in vitro*, in an enzymatic assay using the recombinant 11b-HSD1 enzyme, by measuring the conversion of cortison into cortisol using HPLC purification and quantification methods. 11b-HSD1-reductase inhibition was also demonstrated *in vitro*, in a cell based assay comprising contacting the cells, expressing

11b-HSD1 with the compounds to be tested and assessing the effect of said compounds on the formation of cortisol in the cellular medium of these cells. The cells preferably used in an assay of the present invention are selected from the group consisting of mouse fibroblast 3T3-L1 cells, HepG2 cells, pig kidney cell, in particular LCC-PK1
5 cells and rat hepatocytes.

Accordingly, the present invention provides the compounds of formula (I), (I') and their pharmaceutically acceptable *N*-oxides, addition salts, quaternary amines and stereochemically isomeric forms for use in therapy. More particular in the treatment or
10 prevention of cell proliferation mediated diseases. The compounds of formula (I), (I') and their pharmaceutically acceptable *N*-oxides, addition salts, quaternary amines and the stereochemically isomeric forms may hereinafter be referred to as compounds according to the invention.

15 In view of the utility of the compounds according to the invention, there is provided a method for the treatment of an animal, for example, a mammal including humans, suffering from a cell proliferative disorder such as atherosclerosis, restinosis and cancer, which comprises administering an effective amount of a compound according
20 to the present invention.

Said method comprising the systemic or topical administration of an effective amount of a compound according to the invention, to warm-blooded animals, including humans.

25 It is thus an object of the present invention to provide a compound according to the present invention for use as a medicine. In particular to use the compound according to the present invention in the manufacture of a medicament for treating pathologies associated with excess cortisol formation such as for example, obesity, diabetes, obesity related cardiovascular diseases, and glaucoma.
30

In yet a further aspect, the present invention provides the use of the compounds according to the invention in the manufacture of a medicament for treating any of the aforementioned cell proliferative disorders or indications.

35 The amount of a compound according to the present invention, also referred to here as the active ingredient, which is required to achieve a therapeutical effect will be, of course, vary with the particular compound, the route of administration, the age and condition of the recipient, and the particular disorder or disease being treated. A

suitable daily dose would be from 0.001 mg/kg to 50 mg/kg body weight, in particular from 0.005 mg/kg to 10 mg/kg body weight. A method of treatment may also include administering the active ingredient on a regimen of between one and four intakes per day.

5

While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical composition. Accordingly, the present invention further provides a pharmaceutical composition comprising a compound according to the present invention, together with a pharmaceutically acceptable carrier or diluent. The carrier or diluent must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.

10

The pharmaceutical compositions of this invention may be prepared by any methods well known in the art of pharmacy, for example, using methods such as those described in Gennaro et al. Remington's Pharmaceutical Sciences (18th ed., Mack Publishing Company, 1990, see especially Part 8 : Pharmaceutical preparations and their Manufacture). A therapeutically effective amount of the particular compound, in base form or addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for systemic administration such as oral, percutaneous, or parenteral administration; or topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined

20

25

30

35

with suitable additives of any nature in minor proportions, which additives do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on or as an ointment. As appropriate compositions for topical application there may be cited all compositions usually employed for topically administering drugs e.g. creams, gellies, dressings, shampoos, tinctures, pastes, ointments, salves, powders and the like. Application of said compositions may be by aerosol, e.g. with a propellant such as nitrogen, carbon dioxide, a freon, or without a propellant such as a pump spray, drops, lotions, or a semisolid such as a thickened composition which can be applied by a swab. In particular, semisolid compositions such as salves, creams, gellies, ointments and the like will conveniently be used.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

In order to enhance the solubility and/or the stability of the compounds of formula (I), (I') in pharmaceutical compositions, it can be advantageous to employ α -, β - or γ -cyclodextrins or their derivatives. Also co-solvents such as alcohols may improve the solubility and/or the stability of the compounds of formula (I), (I') in pharmaceutical compositions. In the preparation of aqueous compositions, addition salts of the subject compounds are obviously more suitable due to their increased water solubility.

Experimental part


Hereinafter, the term 'RT' means room temperature, 'THF' means tetrahydrofuran, 'AcOH' means Acetic Acid, 'EtOH' means ethanol, 'DME' means dimethyl ether, 'DIPE' means diisopropyl ether, 'TFA' means trifluoroacetic acid, 'EtOAc' means ethyl acetate, 'iPrOH' means dimethylformamide, 'HOBt' means hydroxybenzotriazole.

A. Preparation of the intermediates

Example A1


5 **Bicyclo[3.3.1]non-2-ylamine (intermediate 4) and 3-azatricyclo[4.3.1.0*2,4*]decane (intermediate 5)**

Preparation of



(interm. 4)

Preparation of




(interm. 5)

10 Bicyclo[3.3.1]nonan-2-one oxime (CAS 16473-10-2) (1.4 g) was dissolved in anhydrous THF (30 ml) and a solution of LiAlH₄ (15 ml, 1M in diethyl ether) was added. The solution was boiled under reflux for 16h. Addition of water (0.6 ml), 15% NaOH (0.6 ml), and water (1.8 mL), followed by filtration, drying of the filtrate (MgSO₄) and evaporation gave the crude amines. The residue was dissolved in CH₂Cl₂, and extracted with 15% citric acid. The aqueous layer was basicified with 1 M KOH, and extracted with CH₂Cl₂. The organic layer was washed with brine, dried and evaporated to give the amines 1:1 mixture (0.5 g).
15 NMR (CDCl₃) δ 1.2-2.1 (m, CH), 2.45 (t, 1H), 2.9 (m, 1H)

Example A2

a) 6-Hydroxyimino-adamantan-2-yl ethylene ketal

Preparation of




Intermediate 16

- 5 Commercially available Spiro[1,3-dioxolane-2,2'-tricyclo[3.3.1.1^{3,7}]decan]-6'-one (CAS 50776-11-9) (2.3 g, 0.012 mol) (containing about 30% of the diketal) was dissolved in EtOH and a solution of hydroxylamine hydrochloride (1.7 g, 0.025 mol) and NaOH (1.0 g) in water (30 ml) was added. The mixture was stirred overnight. The volatiles were evaporated in vacuo, and the residue was extracted with CH₂Cl₂. The organic layer was washed with brine, dried and evaporated to give the oxime
- 10 (Intermediate 16) (2.4 g).

NMR (DMSO-d₆) δ 1.3-2.3 (m, CH), 2.5 (bs, 1H), 3.5 (bs, 1H), 3.95 (s, 4H, CH₂CH₂)

b) 6-Oxo-adamantan-2-ylamine ethylene ketal

Preparation of



Intermediate 17


- 15 6-Hydroxyimino-adamantan-2-yl ethylene ketal (2.4 g) was dissolved &M NH₃/MeOH (100 mL), Raney nickel (1 g) was added and the mixture was hydrogenated at 14 °C. The mixture was filtered, and evaporated to give 2.0 g of the title compound (Intermediate 17).
- 20 NMR (DMSO-d₆) δ 1.3-2.3 (m, CH), 3.23 (bs, 2H, NH₂), 3.95 (s, 4H, CH₂CH₂).

B. Preparation of the compounds

Example B1

N-Adamantan-2-yl-2-(4-chlorophenyl)-isobutyramide

Preparation of



compound 1

2,2-dimethyl-(4-chlorophenyl)acetic acid (CAS 6258-30-6) (2.0 g, 10 mmol) and 2-aminoadamantane hydrochloride (CAS 13074-39-0) (1.9 g, 10 mmol) were dissolved in CH_2Cl_2 (50 mL), HOBT (2.7 g, 20 mmol), triethylamine (2.1 g, 20 mmol), and EDCI (2.1 g, 11 mmol) were added and the mixture was stirred overnight. The reaction mixture was washed with 15% citric acid, sat. NaHCO_3 and brine, dried over MgSO_4 , and evaporated in vacuo. The residue was recrystallised from isopropanol, yielding 2.0 (6 mmol, 60%) of compound 1.


NMR: (DMSO- d_6) δ 1.4-1.8 (m, CH), 1.47 (s, 6H, $(\text{CH}_3)_2$), 3.79 (d, 1H, CH), 6.42 (d, 1H, NH), 7.38 (dd, Ar-H).

LC-MS: M+1 332.89, 334.89

15 Example B2

N-Adamantan-2-yl-2-phenyl-isobutyramide

Preparation of



compound 2


Compound 1 (1.7 g, 5 mmol) was dissolved in MeOH (100 mL), 0.5 g 10% Pd-C and CaO (1 g) were added, and the mixture was hydrogenated at 50 °C. After uptake of one equivalent of hydrogen, the reaction was filtered, evaporated till dryness. The residue was dissolved in CH_2Cl_2 , washed with sat. NaHCO_3 , dried and evaporated. The residue was crystallized from diisopropyl ether, yielding 0.65 g (60%) of the title compound.

NMR: (DMSO- d_6) δ 1.4-1.8 (m, CH), 1.49 (s, 6H, $(\text{CH}_3)_2$), 3.79 (d, 1H, CH), 6.21 (d, 1H, NH), 7.25-7.37 (m, 5H, Ar-H).

25 LC-MS: M+1 298.44

Example B3

Preparation of




compound 3

2,2-dimethylphenyl acetic acid (CAS 826-55-1) was dissolved in dry CH_2Cl_2 , oxalyl chloride was added and one drop of DMF. After stirring for two hours, the solution was evaporated till dryness, redissolved in 10 mL CH_2Cl_2 , and added to a solution of 2-amino adamantane (CAS 13074-39-0) and triethylamine in CH_2Cl_2 . The mixture was stirred overnight, extracted with 15% citric acid, sat. NaHCO_3 and brine, dried over MgSO_4 , and evaporated in vacuo. The residue was recrystallised from isopropyl ether. NMR: (CDCl_3) δ 1.3-1.8 (m, CH), 1.55 (s, 6H, $(\text{CH}_3)_2$), 2.31 (s, 6H, 2 x CH_3), 3.96 (d, 1H, CH), 5.50 (d, 1H, NH), 6.91 (s, 1H, Ar-H), 6.99 (s, 2H, ArH).

Example B4

a) 3-Methoxyphenyl-dimethyl adamantyl acetamide

Preparation of




compound 4

Intermediate 2 (2.0 g, 10 mmol) and 2-aminoadamantane hydrochloride (CAS 13074-39-0) (1.9 g, 10 mmol) were dissolved in CH_2Cl_2 (50 mL), HOBt (2.7 g, 20 mmol), triethylamine (2.1 g, 20 mmol), and EDCI (2.1 g, 11 mmol) were added and the mixture was stirred overnight. The reaction mixture was washed with 15% citric acid, sat. NaHCO_3 and brine, dried over MgSO_4 , and evaporated in vacuo. The residue was recrystallised from isopropanol, yielding 2.0 g (6 mmol, 60%) of compound 4. NMR: ($\text{DMSO}-d_6$) δ 1.4-1.8 (m, CH), 1.48 (s, 6H, $(\text{CH}_3)_2$), 3.75 (s, 3H, OCH_3), 3.79 (d, 1H, CH), 6.23 (d, 1H, NH), 6.8-7.3 (m, 3H, Ar-H).

b) N-Adamantan-2-yl-2-(3-hydroxy-phenyl)-isobutyramide

Preparation of



compound 5


Compound 4 was dissolved in dry CH_2Cl_2 , cooled to -78°C and boron tribromide was added. The reaction mixture was stirred at room temperature for 1 h, poured onto

aqueous ammonia and extracted with C_2Cl_2 . The organic layers were washed with brine, dried and evaporated. The solid residue was crystallized from ethyl acetate. NMR: (DMSO- d_6) δ 1.4-1.8 (m, CH), 1.44 (s, 6H, $(CH_3)_2$), 3.79 (d, 1H, CH), 6.18 (d, 1H, NH), 6.65-7.16 (dd, 4H, Ar-H), 9.35 (s, 1H, OH).

5

c) {3-[1-(Adamantan-2-ylcarbamoyl)-1-methyl-ethyl]-phenoxy}-acetic acid

Preparation of



compound 6

Compound 4 was dissolved in DMF and ethyl bromoacetate was added together with potassium carbonate. The mixture was stirred at 60 °C overnight, poured on ice, and extracted with CH_2Cl_2 . The organic layer was washed with 1 M $NaHCO_3$, and brine, and evaporated. The residue was dissolved in EtOH, 1 M KOH was added, and the mixture was stirred for 2 h. The solution was acidified with 1M HCl, extracted with EtOAc, the organic layer was dried and evaporated. The residue was crystallized from ethyl acetate.

10


15

NMR: (DMSO- d_6) δ 1.4-1.8 (m, CH), 1.47 (s, 6H, $(CH_3)_2$), 3.78 (d, 1H, CH), 4.67 (s, 2H, CH_2COOH), 6.23 (d, 1H, NH), 6.77-7.3 (m, 4H, Ar-H).

Example B5

N-Adamantan-2-yl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-isobutyramide

Preparation of



compound 7

20

Compound 4 was dissolved in DMF, and dimethylaminoethyl chloride hydrochloride was added, followed by K_2CO_3 . The mixture was stirred at 60 °C overnight, poured on ice, and extracted with CH_2Cl_2 . The organic layer was washed with 1 M $NaHCO_3$, and


brine, and evaporated. The residue was dissolved in iPrOH with heating, oxalic acid was added, and the crystalline amine was filtered.

NMR: (DMSO-d₆) δ 1.4-1.8 (m, CH), 1.49 (s, 6H, (CH₃)₂), 2.78 (s, 6H, N(CH₃)₂), 3.43 (t, 2H, CH₂), 3.79 (d, 1H, CH), 4.27 (t, 2H, CH₂), 6.29 (d, 1H, NH), 6.85-7.35 (m, 4H, Ar-H).

Example B6


N-(trans-5-Hydroxy-adamantan-2-yl)-2-phenyl-isobutyramide (Compound 8) and
N-(cis-5-Hydroxy-adamantan-2-yl)-2-phenyl-isobutyramide (Compound 9)

Préparation of



compound 8

Préparation of




compound 9

2,2-dimethylphenyl acetic acid (CAS 826-55-1) (2.5 g, 15 mmol) was dissolved in dry CH₂Cl₂ (50 mL), oxalyl chloride (1.5 mL, 0.017 mol) was added and one drop of DMF. After stirring for two hours, the solution was evaporated till dryness, redissolved in 50 mL of CH₂Cl₂, and added to a solution of 2-amino adamantane (CAS 13074-39-0) (2.5 g, 15 mmol) and triethylamine (3.0 g, 30 mmol) in CH₂Cl₂ (50 mL). The mixture was stirred overnight, extracted with 15% citric acid, sat. NaHCO₃ and brine, dried over MgSO₄, and evaporated in vacuo. The residue was chromatographed over silicagel (eluens 3-5% MeOH in CH₂Cl₂), yielding the title compounds. 1.8 g of trans-, NMR: (CDCl₃) δ 1.2-1.85 (m, CH), 1.59 (s, 6H, (CH₃)₂), 1.95-2.00 (m, 2H, CH), 3.91 (dt, 1H, CH), 5.32 (d, 1H, NH), 7.25-7.47 (m, 5H, Ar-H). And 1.8 g of cis isomer. NMR: (CDCl₃) δ 1.2-1.7 (m, CH), 1.56 (s, 6H, (CH₃)₂), 2.05-2.10 (m, 2H, CH), 3.83 (dt, 1H, CH), 5.32 (d, 1H, NH), 7.25-7.50 (m, 5H, Ar-H).

Example B7

N-(5-trans-fluoro-adamantan-2-yl)-2-phenyl-isobutyramide

Preparation of



compound 10.


Compound 8 (80 mg) was dissolved in dichloromethane (2 mL) and cooled to -78°C under nitrogen. DAST ((diethylamino)sulfur trifluoride, 0.1 mL) was added, and the mixture was stirred and warmed to room temperature. Sat. NaHCO_3 was added and the layers were separated. The organic layer was washed with brine, dried (MgSO_4) and evaporated. The residue was crystallized from diisopropylether to give 40 mg (50%) of the title compound.

NMR: (CDCl_3) δ 1.2-1.85 (m, CH), 1.59 (s, 6H, $(\text{CH}_3)_2$), 1.95-2.10 (m, 2H, CH), 3.93 (dt, 1H, CH), 5.27 (d, 1H, NH), 7.27-7.43 (m, 5H, Ar-H).

Example B8

N-(5-Bromo-adamantan-2-yl)-2-(3-hydroxy-phenyl)-isobutyramide

Preparation of



compound 11.

Compound 8 (100 mg, 0.3 mmol) was dissolved in CH_2Cl_2 (2 mL), cooled to -78°C and boron tribromide (0.15 mL, 1.5 mmol) was added. The reaction mixture was warmed to room temperature, diluted with CH_2Cl_2 and poured on a mixture ice and conc. Ammonia. The layers were separated, the organic layer washed with brine, dried (MgSO_4) and evaporated. The residue was crystallized from ethyl acetate (40 mg, 40%).


LC-MS: $\text{M}+1$ 393.34, 395.34

NMR: (CDCl_3) δ 1.25-1.52 (m, CH), 1.57 (s, 6H, $(\text{CH}_3)_2$), 1.90-2.42 (m, CH), 3.97 (dt, 1H, CH), 5.37 (d, 1H, NH), 6.28-7.30 (m, 4H, Ar-H).

Example B9

N-(6-Oxo-adamantan-2-yl)-2-phenyl-isobutyramide ethylene ketal

Preparation of



compound 12


2,2-dimethylphenyl acetic acid (CAS 826-55-1) (0.5 g, 2.7 mmol) was dissolved in dry CH_2Cl_2 , oxalyl chloride (0.4 g) was added and one drop of DMF. After stirring for two hours, the solution was evaporated till dryness, redissolved in 10 mL CH_2Cl_2 , and added to a solution of 6-oxo-adamantan-2-ylamine ethylene ketal (Intermediate 15) (0.6 g, 2.7 mmol) and triethylamine (0.5 mL) in CH_2Cl_2 . The mixture was stirred overnight, extracted with 15% citric acid, sat. NaHCO_3 and brine, dried over MgSO_4 , and evaporated in vacuo. The residue was purified over silicalgel (eluens 5% MeOH in CH_2Cl_2), and the title compound was recrystallised from isopropyl ether. 600 mg (50%)

NMR: (CDCl_3) δ 1.52-2.05 (m, CH), 1.60 (s, 6H, $(\text{CH}_3)_2$), 3.85 (dt, 1H, CH), 3.85-3.90 (m, 4H, CH_2CH_2), 5.45 (d, 1H, NH), 7.23-7.42 (m, 5H, Ar-H).

Example B10

N-(6-Oxo-adamantan-2-yl)-2-phenyl-isobutyramide

Preparation of




compound 13

The ketal from example B9 (450 mg) was dissolved in acetone (10 mL), 1 M HCl (5 mL) was added and the mixture was stirred for 3 h at 45 °C. The reaction mixture was concentrated, and extracted with dichloromethane. The organic layers were washed with sat. NaHCO_3 and brine, dried and evaporated. The residue was crystallized from ethanol: 300 mg of the title compound.

NMR: (CDCl_3) δ 1.52-1.75 (m, CH), 1.60 (s, 6H, $(\text{CH}_3)_2$), 1.95-2.15 (m, 2H, CH), 2.30 (d, 2H, CH), 2.50 (s, 2H, CH), 4.12 (dt, 1H, CH), 5.45 (d, 1H, NH), 7.27-7.47 (m, 5H, Ar-H).

Example B11

N-(6-Hydroxy-adamantan-2-yl)-2-phenyl-isobutyramide




Preparation of

compound 14

Compound 13 (50 mg) was dissolved in MeOH and NaBH₄ (50 mg) was added. The mixture was stirred at room temperature for 6 h. 1M HCl was added, and the mixture was extracted with dichloromethane. The organic phase was washed with brine, dried and evaporated. Chromatography over silicagel (5% MeOH in CH₂Cl₂) gave the alcohol (20 mg, 40%)

NMR: (CDCl₃) δ 1.52-2.00 (m, CH), 1.60 (s, 6H, (CH₃)₂), 3.85 (dt, 1H, CH), 5.45 (d, 1H, NH), 7.23-7.42 (m, 5H, Ar-H).

Example B13




Preparation of

compound 17

1-Phenylcyclopropanecarboxylic acid (0.00028 mol); was added to a mixture of PS-N-cyclohexylcarbodiimide (0.0004 mol) in CH₂Cl₂ (5 ml). The mixture was stirred for 15 min. 2-methyl-2-Propanamine (0.0002 mol) was added and the reaction mixture was stirred overnight at room temperature. The resin was filtered off and the filtrate was evaporated. The residue was purified over Supelclean LC-SI (14 ml; eluent: CH₂Cl₂). The product fractions were collected and the solvent was evaporated, yielding compound 17.

Example B14



Preparation of

compound 31


PS-carbodiimide (0.0004 mol) was suspended in CH₂Cl₂ (5 ml). Then, 1-phenylcyclopropanecarboxylic acid (0.00028 mol) and N,N-dimethyl-4-pyridinamine






(0.00001mol) were added and the mixture was stirred for 20 min.


















Tricyclo[3.3.1.1^{3,7}]decane-1-methanamine (0.0002 mol; 6 variables) was added and the reaction mixture was stirred overnight at room temperature. The mixture was filtered. The filter residue was washed with CH₂Cl₂ and the filtrate's solvent was evaporated. The residue was purified by flash column chromatography on Triconex flash tubes (eluent: hexane/EtOAc 9/2). The product fractions were collected and then extracted and the extracts were evaporated. Yielding 0.037 of compound 31




















Tables 1, 2 and 3 list compounds of the present invention as prepared according to one of the above examples.





















Table 1









































Co. No.	Ex No.	R ¹	R ²		---R ³	T	Physical data
16	B3	-	-	-(CH ₂) ₃ -		-	
17	B13	-	-	-(CH ₂) ₂ -	-C(CH ₃) ₃	-	
18	B13	-	-	-(CH ₂) ₂ -	-C(CH ₃) ₂ -CH ₂ - C(CH ₃) ₃	-	
19	B13	-	-	-(CH ₂) ₂ -		-	
20	B13	-	-	-(CH ₂) ₂ -		-	
21	B13	-	-	-(CH ₂) ₄ -	-C(CH ₃) ₃	-	
22	B13	-	-	-(CH ₂) ₄ -		-	















Co. No.	Ex No.	R ¹	R ²	$\overset{\text{R}^1}{\text{---}} \overset{\text{R}^2}{\text{---}}$	---R ³	T	Physical data
23	B13	-	-	-(CH ₂) ₄ -		-	
24	B13	-	-	-(CH ₂) ₄ -		-	
25	B13	-	-	-(CH ₂) ₅ -		-	
26	B13	-	-	-(CH ₂) ₅ -		-	
1	B1	CH ₃	CH ₃	-		4-Cl	
27	B1	-	-	-(CH ₂) ₂ -		4-Cl	
28	B1	CH ₃	-	-		-	
2	B2	CH ₃	CH ₃	-		-	
29	B1	C ₂ H ₅	-	-		-	
30	B1	-	-	-		-	
31	B14	-	-	-(CH ₂) ₂ -		-	
32	B1	-	-	-(CH ₂) ₂ -		-	
33	B14	-	-	-(CH ₂) ₂ -		-	
34	B14	-	-	-(CH ₂) ₂ -		-	
35	B14	-	-	-(CH ₂) ₄ -		-	
36	B14	-	-	-(CH ₂) ₄ -		-	
37	B14	-	-	-(CH ₂) ₆ -		-	


















Co. No.	Ex No.	R ¹	R ²		---R ³	T	Physical data
38	B1	-	-	-(CH ₂) ₄ -		-	
39	B1	-	-	-(CH ₂) ₃ -		4-Cl	
40	B2	-	-	-(CH ₂) ₃ -		-	
41	B1	CH ₃	CH ₃	-		4-F	-
42	B1		-	-		-	
43	B1	CH ₃ O	-	-		-	
44	B1		-C(CH ₃) ₃ -O-CO-NH	-		-	
45	B1	CH ₃	CH ₃	-		-	
46	B1	CH ₃	CH ₃	-		-	
4	B4	CH ₃	CH ₃	-		3-OCH ₃	
47	B4	CH ₃	CH ₃	-		4-OCH ₃	
48	B4	CH ₃	CH ₃	-		-	
49	B1	-	-	-(CH ₂) ₂ -		-	
5	B4	CH ₃	CH ₃	-		3-OH	
50	B1	-NH ₂	-	-		-	
51	B1	-NH ₂	-	-		-	isomeric form of comp 50

Co. No.	Ex No.	R ¹	R ²	$\overset{\text{R}^1}{\text{---}} \overset{\text{R}^2}{\text{---}}$	---R ³	T	Physical data
52	B1	CH ₃	CH ₃	-		4-N(CH ₃) ₂	
53	B5	CH ₃	CH ₃	-		3-O-(CH ₂) ₂ -CH ₃	
54	B5	CH ₃	CH ₃	-		3-O-(CH ₂) ₂ -CH ₃ -N 	
55	B14	-	-	-(CH ₂) ₂ -		-	
56	B14	-	-	-(CH ₂) ₂ -		-	
57	B14	-	-	-(CH ₂) ₄ -		-	
58	B14	-	-	-(CH ₂) ₄ -		-	
59	B14	-	-	-(CH ₂) ₅ -		-	
60	B14	-	-	-(CH ₂) ₅ -		-	
61	B1	-	-	-(CH ₂) ₂ -		-	
62	B1	CH ₃	CH ₃	-		-	
63	B1	CH ₃	CH ₃	-		-	
64	B1	-	-	-(CH ₂) ₂ -		-	
6	B4	CH ₃	CH ₃	-		3-O-(CH ₂) ₂ -COOH	
65	B5	CH ₃	CH ₃	-		3-O-(CH ₂) ₂ -N 	
9	B6	CH ₃	CH ₃	-		-	
66	B1		-	-		-	

Co. No.	Ex No.	R ¹	R ²		---R ³	T	Physical data
67	B1	CH ₃	CH ₃	-			
68	B1	CH ₃	-	-			
69	B1	-	-	-			
70	B4	CH ₃	CH ₃	-		4-OH	
71	B5	CH ₃	CH ₃	-		3-O-(CH ₂) ₂ -N	
7	B5	CH ₃	CH ₃	-		3-O-(CH ₂) ₂ -N(CH ₃) ₂	
72	B1	CH ₃	CH ₃	-		4-O-CH ₂ -COOH	
73	B5	CH ₃	CH ₃	-		4-O-(CH ₂) ₂ -N	
74	B4	CH ₃	CH ₃	-		3-O-CH ₃	
75	B4	CH ₃	CH ₃	-		3-O-CH ₃	
76	B1	CH ₃	CH ₃	-		3-NH ₂	
77	B1	CH ₃	CH ₃	-		3-NH-CH ₃	
78	B1	CH ₃	CH ₃	-		3-N(CH ₃) ₂	
79	B1	CH ₃	CH ₃	-		4-NH ₂	
80	B1	CH ₃	CH ₃	-		4-NH-CH ₃	
81	B1	CH ₃	CH ₃	-		4-N(CH ₃)-(CH ₂)-C ₆ H ₅	

Co. No.	Ex No.	R ¹	R ²		----R ³	T	Physical data
82	B1	-N(CH ₃) ₂	-	-		-	
83	B1	CH ₃	CH ₃	-		3-Cl	
84	B1	CH ₃	CH ₃	-		3-F	
85	B1	CH ₃	CH ₃	-		3-CF ₃	
86	B1	CH ₃	CH ₃	-		3,4 (-OCH ₃) ₂	
87	B1	CH ₃	CH ₃	-		2,4 -F ₂	
88	B1	CH ₃	CH ₃	-		2,5 -F ₂	
89	B1	CH ₃	CH ₃	-		3-CH ₃	
90	B1	CH ₃	CH ₃	-		-	
91	B1	CH ₃	CH ₃	-		-	
92	B5	CH ₃	CH ₃	-		3-O-(CH ₂) ₃ -N(CH ₃) ₂	
8	B6	CH ₃	CH ₃	-		-	
93	B1	CH ₃	CH ₃	-		2,5 (-O-CH ₃)	
94	B1	CH ₃	CH ₃	-		2-O-C ₆ H ₅	
95	B1	CH ₃	CH ₃	-		3,5 F ₂	
96	B3	CH ₃	CH ₃	-		-	isomeric form of comp 90
97	B3	CH ₃	CH ₃	-		-	

Co. No.	Ex No.	R ¹	R ²		----R ³	T	Physical data
98	B3	CH ₃	CH ₃	-		-	isomeric form of comp 97
99	B3	CH ₃	CH ₃	-		-	
100	B3	CH ₃	CH ₃	-		-	isomeric form of comp 99
101	B3	CH ₃	CH ₃	-		-	
102	B3	CH ₃	CH ₃	-		-	isomeric form of comp 101
103	B3	CH ₃	CH ₃	-		-	isomeric form of comp 102
104	B3	CH ₃	CH ₃	-		-	isomeric form of comp 103
105	B3	CH ₃	CH ₃	-		-	
106	B1	CH ₃	CH ₃	-		2,4 Cl ₂	
3	B1	CH ₃	CH ₃	-		3,5 (CH ₃) ₂	
107	B1	CH ₃	CH ₃	-		3-NH-CO-(CH ₂) ₃ -Cl	
108	B6	CH ₃	CH ₃	-		-	
109	B6	CH ₃	CH ₃	-		-	

Co. No.	Ex No.	R ¹	R ²	R ¹ R ²	-----R ³	T	Physical data
110	B3	CH ₃	CH ₃	-	mixture of 	-	
111	B3	CH ₃	CH ₃	-		-	
12	B9	CH ₃	CH ₃	-		-	
112	B4	CH ₃	CH ₃	-		3-NH-CO-CH ₃	
113	B1	CH ₃	CH ₃	-		3-N 	
114	B5	CH ₃	CH ₃	-		3-N 	
115	B5	CH ₃	CH ₃	-		3-N-(CH ₂) ₂ -O-CH ₃ (CH ₂) ₂ O CH ₃	
116	B5	CH ₃	CH ₃	-		3-N 	
13	B10	CH ₃	CH ₃	-		-	
14	B11	CH ₃	CH ₃	-		-	
117	B6	CH ₃	CH ₃	-		3-O-CH ₃	
118	B6	CH ₃	CH ₃	-		3-O-CH ₃	
119	B6	CH ₃	CH ₃	-		3-CH ₃	pound
120	B6	CH ₃	CH ₃	-		3-CH ₃	














































Co. No.	Ex. No.	R ¹	R ²	$\overset{\text{R}^1}{\text{---}} \overset{\text{R}^2}{\text{---}}$	---R ³	T	Physical data
121	B6	CH ₃	CH ₃	-		3,5 (-CH ₃) ₂	
122	B6	CH ₃	CH ₃	-		3,5 (-CH ₃) ₂	isomeric form of comp 121
10	B7	CH ₃	CH ₃	-		-	
123	B1	CH ₃	CH ₃	-		3-N(CH ₃)-CO-CH ₃	
11	B8	CH ₃	CH ₃	-		3-OH	

Table 2



5

Co. No.	Ex. No.	Q	n	R ¹	R ²	R ³	R ⁴	Physical data
124	B3		0	-	-	H		
125	B3		0	-	-	-		
126	B1		0	-	-	H		
127	B1		0	-	-	H		
128	B6		1	CH ₃	CH ₃	H		

129	B1		2	N(C H ₃) ₂	H	H		
130	B1		1	H	H	H		
131	B5	-O-CH ₂ -COOH	1	CH ₃	CH ₃	H		
132	B3		1	CH ₃	CH ₃	CH ₃		
133	B1		1	CH ₃	CH ₃	H		
134	B1		1	CH ₃	CH ₃	H		
135	B1		1	CH ₃	CH ₃	H		
136	B1		1	CH ₃	CH ₃	H		
137	B1		1	CH ₃	CH ₃	H		
138	B1		1	CH ₃	CH ₃	H		
139	B1		1	H	H	H		
140	B1		2	CH ₃	H	H		
141	B1		0	-	-	H		
142	B1		1	CH ₃	CH ₃	H		
143	B1		2	CH ₃	CH ₃	H		























144	B1		2	CH ₃	CH ₃	H		
145	B1		0	-	-	H		
146	B1		1	=O	-	H		
147	B1		1	CH ₃	CH ₃	H		
148	B6		1	CH ₃	CH ₃	H		
149	B6		1	CH ₃	CH ₃	H		
150	B4		0	-	-	H		
172	B1	2,5 methoxy-phenyl	1	CH ₃	CH ₃	H		

Table 3



Co. No.	Ex. No.	Q	R ¹	R ²	R ³	R ⁴	Physical data
151	B1		H	CH ₃	H		
152	B1		H	H	H		
153	B1		CH ₃	H	H		

5

C. Pharmacological examples

Example C.1 : Enzymatic assays to test the effect of compounds on 11b-hydroxysteroid dehydrogenase type 1 and type 2

- 10 The effects of compounds on 11b-HSD1 dependent conversion of cortisone into cortisol (**reductase** activity) was studied in a reaction mixture containing 30 mM Tris-HCl buffer pH 7.2, 180 μ M NADPH, 1mM EDTA, 2 μ M cortisone, 1 μ l drug and/or solvent and 11 μ g recombinant protein in a final volume of 100 μ l.
- 15 The effect on the 11b-HSD1-**dehydrogenase** activity (conversion of cortisol into cortisone) was measured in a reaction mixture containing 0.1M sodium phosphate buffer pH 9.0, 300 μ M NADP, 25 μ M cortisol, 1 μ l drug and/or solvent and 3.5 μ g recombinant protein in a final volume of 100 μ l.
- 20 The effects on the 11b-HSD2 dependent **dehydrogenase** activity was studied in a reaction mixture containing 0.1M sodium phosphate buffer pH 7.5, 300 μ M NAD, 100 nM cortisol (of which 2 nM is 3H-radio labelled), 1 μ l drug and/or solvent and 2.5 μ g recombinant protein in a final volume of 100 μ l.

All incubations were performed for 45 min at 37C in a water bath. The reaction was stopped by adding 100 µl acetonitrile containing 20 µg corticosterone as internal standard. After centrifugation, the product formation was analysed in the supernatant by HPLC on a Hypersyl BDS-C18 column using 0.05 mM ammonium acetate / methanol (50/50) as solvent. In all of the aforementioned assays, the drugs to be tested were taken from a stock solution and tested at a final concentration ranging from 10^{-5} M to 3.10^{-9} M. From the thus obtained dose response curves, the pIC50 value was calculated and scored as follows; Score 1 = pIC50 value < 5, Score 2 = pIC50 value in the range of 5 to 6, Score 3 = pIC50 value > 6. Some of the thus obtained results are summarized in the table below. (in this table NT stands for Not Tested).

Example C2 : Cellular assays to test the effect of compounds on 11b-hydroxysteroid dehydrogenase type 1 and type 2

The effects on 11b-HSD1 activity was measured in differentiated 3T3-L1 cells and rat hepatocytes.

Mouse fibroblast 3T3-L1 cells (ATCC-CL-173) were seeded at a density of 16500 cells / ml in 12 well plates and grown for 7 days in DMEM medium (supplemented with 10 % heat inactivated foetal calf serum, 2mM glutamine and 25 mg gentamycin) at 37C in a humidified 5% CO2 atmosphere. Medium was refreshed twice a week. Fibroblasts were differentiated into adipocytes at 37C in a 5% CO2 humidified atmosphere in growth medium containing 2µg/ml insulin, 55 µg/ml IBMX and 39.2 µg/ml dexamethasone.

Primary hepatocytes from male rats were seeded on BD-Biocoat Matrigel matrix multiwell plates at a density of 250000 cells /well and incubated for 10 days at 37C in a 5% CO2 humidified atmosphere in DMEM-HAM's F12 medium containing 5% Nu-serum, 100 U/ml penicillin, 100 µg/ml streptomycin , 0.25 µg/ml amphotericin B, 50 µg/ml gentamycin sulfate, 5µg/ml insulin and 392 ng/ml dexamethasone. Medium was refreshed 3 times a week.

Following a 4 hour pre-incubation with test compound, 0.5 µCi 3 H-cortisone or dehydrocorticosterone, was added to the cultures. One hour later, the medium was extracted on Extrelut³-columns with 15 ml diethyl ether and the extract was analysed by HPLC as described above.

The effects on 11b-HSD2 activity was studied in HepG2 and LCC-PK1-cells

HepG2-cells (ATCC HB-8065) were seeded in 12 well plates at a density of 100,000 cells/ml and grown at 37°C in a humidified 5% CO₂ atmosphere in MEM-Rega-3 medium supplemented with 10% heat inactivated foetal calf serum, 2 mM L-glutamine and sodium bicarbonate). Medium was refreshed twice a week.

5 Pig kidney cells (LCC-PK1, ATCC CRL-1392) were seeded at a density of 150,000 cells /ml in 12 well plates and grown at 37°C in a humidified 5% CO₂ atmosphere in Medium 199 supplemented with Earls modified salt solution, 100 U/ml penicillin, 100 µg/ml streptomycin and 10 % foetal calf serum. Medium was refreshed twice a week. Twenty four hours prior to the onset of the experiment, medium was changed by
10 medium containing 10% charcoal stripped foetal calf serum.

Following a 4 hour pre-incubation with test compound, 0.5 µCi ³H-cortisol or corticosterone, was added to the cultures. One hour later, the medium was extracted on Extrelut³-columns with 15 ml diethyl ether and the extract was analysed by HPLC as described above.

15 As for the enzymatic assays, the compounds to be tested were taken from a stock solution and tested at a final concentration ranging from - 10⁻⁵M to 3.10⁻⁹M. From the thus obtained dose response curves, the pIC₅₀ value was calculated and scored as follows; Score 1 = pIC₅₀ value < 5, Score 2 = pIC₅₀ value in the range of 5 to 6, Score
20 3 = pIC₅₀ value >6. Some of the thus obtained results are summarized in the table below. (in this table NT stands for Not Tested).

Example Number	Compound Number	[C1] HSD1-prot Reduct	[C1] HSD2 cellular HepG2	[C2] HSD1 cellular 3T3-L1	[C2] HSD2 cellular HepG2
		Score	Score	Score	Score
B3	16	NT	1	2	1
B13	19	NT	1	2	1
B13	22	NT	1	2	1
B1	1	NT	1	3	1

Example Number	Compound Number	[C1] HSD1-prot Reduct	[C1] HSD2 cellular HepG2	[C2] HSD1 cellular 3T3-L1	[C2] HSD2 cellular HepG2
		Score	Score	Score	Score
B1	28	NT	NT	3	1
B1	29	NT	NT	3	1
B1	30	NT	NT	3	1
B14	31	NT	1	3	1
B14	35	NT	1	2	1
B1	41	3	1	3	1
B1	43	3	1	2	1
B1	46	1	1	3	1
B4	47	3	1	3	1
B4	48	1	1	3	1
B1	126	3	1	3	1
B1	127	1	1	3	1
B4	5	3	1	3	1
B1	50	1	1	2	1
B1	51	1	1	2	1
B1	52	1	1	3	1
B5	53	1	1	3	1
B5	54	2	1	3	1
B14	55	NT	1	3	1
B14	56	NT	1	2	1
B14	57	NT	1	2	1
B1	64	NT	1	2	1
B4	6	2	1	3	1
B6	128	3	1	3	1
B1	129	2	1	2	1
B1	68	2	1	2	1
B5	71	3	NT	3	1
B5	7	1	NT	3	1
B1	72	2	1	3	1
B5	73	1	1	3	1
B4	74	3	1	3	1

Example Number	Compound Number	[C1] HSD1-prot Reduct	[C1] HSD2 cellular HepG2	[C2] HSD1 cellular 3T3-L1	[C2] HSD2 cellular HepG2
		Score	Score	Score	Score
B1	133	1	1	3	1
B1	77	1	2	3	1
B1	78	3	2	3	1
B1	81	3	NT	2	1
B1	84	1	1	3	1
B1	85	1	1	3	1
B1	86	1	1	3	1
B1	87	1	1	3	1
B1	88	1	1	3	1
B1	89	3	1	3	1
B1	137	3	1	3	1
B1	138	1	1	3	1
B1	91	1	1	3	1
B1	151	2	1	3	1
B1	153	2	1	3	1
B1	140	3	1	3	1
B1	141	3	1	3	1
B1	92	3	1	3	1
B1	93	3	NT	3	1
B1	173	1	NT	3	1
B1	95	1	NT	3	1
B1	144	3	NT	3	1
B1	106	1	NT	3	1
B1	3	3	NT	3	1
B6	109	3	NT	3	1

D. Composition examples

The following formulations exemplify typical pharmaceutical compositions suitable for systemic or topical administration to animal and human subjects in accordance with the present invention.

- 5 "Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I) or a pharmaceutically acceptable addition salt thereof.

Example D.1 : film-coated tablets

Preparation of tablet core


- 10 A mixture of A.I. (100 g), lactose (570 g) and starch (200 g) was mixed well and thereafter humidified with a solution of sodium dodecyl sulfate (5 g) and polyvinylpyrrolidone (10 g) in about 200 ml of water. The wet powder mixture was sieved, dried and sieved again. Then there was added microcrystalline cellulose (100 g) and hydrogenated vegetable oil (15 g). The whole was mixed well and compressed into tablets, giving 10.000 tablets, each comprising 10 mg of the active ingredient.

Coating

- 15 To a solution of methyl cellulose (10 g) in denaturated ethanol (75 ml) there was added a solution of ethyl cellulose (5 g) in CH_2Cl_2 (150 ml). Then there were added CH_2Cl_2 (75 ml) and 1,2,3-propanetriol (2.5 ml). Polyethylene glycol (10 g) was molten and dissolved in dichloromethane (75 ml). The latter solution was added to the former and then there were
20 added magnesium octadecanoate (2.5 g), polyvinyl-pyrrolidone (5 g) and concentrated color suspension (30 ml) and the whole was homogenated. The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Claims

1. A compound having the formula



the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein


n represents an integer being 0, 1 or 2;

m represents an integer being 0 or 1;

R^1 and R^2 each independently represents hydrogen, C_{1-4} alkyl, NR^9R^{10} , C_{1-4} alkyloxy, $\text{Het}^3\text{-O-C}_{1-4}$ alkyl; or

R^1 and R^2 taken together with the carbon atom with which they are attached form a carbonyl, or a C_{3-6} cycloalkyl; and where *n* is 2, either R^1 or R^2 may be absent to form an unsaturated bond;

R^3 represents hydrogen, Ar^1 , C_{1-8} alkyl, C_{6-12} cycloalkyl or a monovalent radical having one of the following formulae



wherein said Ar^1 , C_{6-12} cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two or three substituents selected from the

group consisting of C₁₋₄alkyl, C₁₋₄alkyloxy, phenyl, halo, oxo, carbonyl, 1,3-dioxolyl or hydroxy;

R⁴ represents hydrogen or C₁₋₄alkyl;

Q represents C₃₋₈cycloalkyl, Het¹ or Ar², wherein said C₃₋₈cycloalkyl, Het¹ or Ar² are optionally substituted with one or where possible more substituents selected from halo, C₁₋₄alkyl, C₁₋₄alkyloxy, hydroxy, nitro, Het⁴, phenyl, phenyloxy, C₁₋₄alkyloxycarbonyl, hydroxycarbonyl, NR⁵R⁶, C₁₋₄alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het² and NR⁷R⁸, and

C₁₋₄alkyl substituted with one or where possible two or three halo substituents;

R⁵ and R⁶ are each independently selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkyloxy, C₁₋₄alkyl, C₁₋₄alkyloxycarbonyl, C₁₋₄alkylcarbonyl, C₁₋₄alkylcarbonyl substituted with one or where possible two or three substituents each independently selected from halo, C₁₋₄alkyl, and C₁₋₄alkyloxy or R⁵ and R⁶ each independently represent C₁₋₄alkyl substituted with phenyl;

R⁷ and R⁸ are each independently selected from hydrogen or C₁₋₄alkyl;

R⁹ and R¹⁰ are each independently selected from hydrogen, C₁₋₄alkyl or C₁₋₄alkyloxycarbonyl;

L represents C₁₋₄alkyl optionally substituted with one or where possible more substituents selected from C₁₋₄alkyl or phenyl;

Het¹ represents a heterocycle selected from pyridinyl, piperidinyl, pyrimidinyl, pyrazinyl, piperazinyl, pyridazinyl, indolyl, isoindolyl, indolinyl, furanyl, benzofuranyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, benzothiophenyl, thiophenyl, 1,8-naphthyridinyl, 1,6-naphthyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, phthalazinyl, or 1,3-benzodioxolyl;

Het² represents a monocyclic heterocycle selected from piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 2H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, or morpholinyl;

Het³ represents a monocyclic heterocycle selected from 2H-pyranyl, 4H-pyranyl, furanyl, tetrahydro-2H-pyranyl, pyridinyl, piperidinyl, or furanyl;

Het⁴ represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het⁴ optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy;

Ar¹ represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, biphenyl, indenyl, 2,3-dihydroindenyl, fluorenyl, 5,6,7,8-tetrahydronaphthyl or naphthyl

Ar^2 represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, biphenyl, indenyl, 2,3-dihydroindenyl, fluorenyl, 5,6,7,8-tetrahydronaphtyl or naphtyl.

- 5 2. A compound according to claim 1 wherein;
 n represents an integer being 1 or 2 provided that when n represents 2, Q represents Het^1 or Ar^2 , wherein said Het^1 or Ar^2 are optionally substituted with one or where possible more substituents selected from halo, C_{1-4} alkyl, C_{1-4} alkyloxy, hydroxy, nitro, Het^4 , phenyl, phenyloxy, hydroxycarbonyl, NR^5R^6 , C_{1-4} alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het^2 and NR^7R^8 , and
 C_{1-4} alkyl substituted with one or where possible two or three halo substituents

- 15 3. A compound according to anyone of claims 1 or 2 wherein;
 Het^1 represents a heterocycle selected from piperinidyl, pyrimidinyl, pyrazinyl, piperazinyl, pyridazinyl, indolyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, 1,8-naphthyridinyl, 1,6-naphthyridinyl, quinazolinyl, phthalazinyl; or 1,3-benzodioxolyl

- 20 4. A compound according to claim 1 wherein;
 Q represents phenyl, said phenyl optionally substituted with one or two substituents selected from the halo, preferably chloro or fluor, or C_{1-4} alkyloxy preferably methoxy;

n is 1;


25 m is 0;

R^1 and R^2 represent C_{1-4} alkyl, preferably methyl;

R^1 and R^2 taken together with the carbon atom with which they are attached form a C_{3-6} cycloalkyl, preferably cyclopropyl;


R^4 represents hydrogen;

30 R^3 represents a monovalent radical having one of the following formulae




wherein said monovalent radical may optionally be substituted with one or where possible two or three substituents selected from halo, carbonyl, hydroxy or C₁₋₄alkyloxy, preferably methoxy.

- 5 5. A compound according to claim 1 wherein;
 n represents an integer being 1 or 2;
 R¹ and R² each independently represents hydrogen C₁₋₄alkyl, NR⁹R¹⁰; or
 R¹ and R² taken together with the carbon atom with which they are attached form a C₃₋₆cycloalkyl; and where n is 2, either R¹ or R² may be absent to form an
 10 unsaturated double bond;
 R³ represents a C₆₋₁₂cycloalkyl or a monovalent radical having one of the following formulae




- 15 wherein said C₆₋₁₂cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkyloxy, halo or hydroxy;
 Q represents Het¹ or Ar² wherein said Het¹ or Ar² are optionally substituted with one or where possible two or more substituents selected from halo, C₁₋₄alkyl, C₁₋₄alkyloxy, hydroxy, NR⁵R⁶, C₁₋₄alkyloxy substituted with one or where possible
 20 two, three or more substituents each independently selected from hydroxycarbonyl, Het² and NR⁷R⁸, and C₁₋₄alkyl substituted with one or where possible two or three halo substituents;
 R⁵ and R⁶ each independently represent hydrogen or C₁₋₄alkyl;
 R⁹ and R¹⁰ each independently represent hydrogen or C₁₋₄alkyloxycarbonyl;
 25 L represents C₁₋₄alkyl;
 Het¹ represents a heterocycle selected from pyridinyl, piperidinyl, thiophenyl or 1,3-benzodioxol;
 Het² represents pyridinyl, pyrrolidinyl or morpholinyl;
 Ar² represents phenyl, naphthyl or indenyl.

6. A compound according to claim 5 wherein;
 R^1 and R^2 each independently represents hydrogen C_{1-4} alkyl; or
 R^1 and R^2 taken together with the carbon atom with which they are attached form a C_{3-6} cycloalkyl; and where n is 2, either R^1 or R^2 may be absent to form an unsaturated double bond;
 R^3 represents a C_{6-12} cycloalkyl, preferably cylo-octanyl or a monovalent radical having one of the following formulae



wherein said C_{6-12} cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkyloxy, halo or hydroxy.

7. A compound according to claim 1 wherein
n represents an integer being 1 or 2;
 R^1 and R^2 each independently represents hydrogen C_{1-4} alkyl, NR^9R^{10} , C_{1-4} alkyloxy; or
 R^1 and R^2 taken together with the carbon atom with which they are attached form a C_{3-6} cycloalkyl; and where n is 2, either R^1 or R^2 may be absent to form an unsaturated double bond;
 R^3 represents a C_{6-12} cycloalkyl, preferably selected from cylo-octanyl and cyclohexyl or R^3 represents a monovalent radical having one of the following formulae



wherein said C₆₋₁₂cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkyloxy, halo or hydroxy;

Q represents C₃₋₈cycloalkyl, Het¹ or Ar² wherein said Het¹ or Ar² are optionally substituted with one or where possible two or more substituents selected from halo, C₁₋₄alkyl, C₁₋₄alkyloxy, hydroxy, nitro, NR⁵R⁶, C₁₋₄alkyloxy substituted with one or where possible two, three or more substituents each independently selected from hydroxycarbonyl, Het² and NR⁷R⁸, and C₁₋₄alkyl substituted with one or where possible two or three halo substituents, preferably trifluoromethyl;

R⁵ and R⁶ each independently represent hydrogen, C₁₋₄alkyl, or C₁₋₄alkyl substituted with phenyl;

L represents C₁₋₄alkyl;

Het¹ represents a heterocycle selected from pyridinyl, piperidinyl, or thiophenyl;

Het² represents piperidinyl, pyrrolidinyl or morpholinyl;

Ar² represents phenyl, naphthyl or indenyl.

8. A compound as claimed in claim 1 wherein the compound is

(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-benzeneacetamide;

(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-methyl-benzeneacetamide;

(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-methoxy-benzeneacetamide;

(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-hydroxy-benzeneacetamide;

(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3,5-dimethyl-benzeneacetamide);

(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)-3-(phenylmethoxy)benzeneacetamide;


(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-(carboxymethoxy)-benzeneacetamide;

(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-[2-(4-morpholinyl)ethoxy]-benzeneacetamide;


(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-fluorotricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-benzeneacetamide;

(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-methoxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-benzeneacetamide;

- (1 α ,2 α ,3 β ,5 β ,7 β)-N-(5-methoxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-benzeneacetamide;
N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-benzeneacetamide;
N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-(carboxymethoxy)-
5 benzeneacetamide;
N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-[2-(4-morpholinyl)ethoxy]-
benzeneacetamide;
N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3,5-dimethoxy-
benzeneacetamide;
10 N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-methyl-benzeneacetamide;
N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-methoxy-benzeneacetamide;
N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-hydroxy-benzeneacetamide;
N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3,5-dimethyl-benzeneacetamide;
N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-4-fluoro-benzeneacetamide;
15 N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)-1-phenyl-cyclopropanecarboxamide;
N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-2,6-difluoro-benzeneacetamide;
or
N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-2-thiopheneacetamide; a *N*-
oxide, a pharmaceutically acceptable addition salt or a stereochemically
20 isomeric form thereof.
9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier
and, as active ingredient, an effective 11 β -HSD1 inhibitory amount of a compound
as described in any one of claims 1 to 8.
25
10. A process of preparing a pharmaceutical composition as defined in claim 8,
characterized in that, a pharmaceutically acceptable carrier is intimately mixed
with an effective 11 β -HSD1 inhibitory amount of a compound as described in any
one of claims 1 to 8.
30
11. A compound as claimed in any one of claims 1 to 8 for use as a medicine.
12. Use of a compound as claimed in any one of claims 1 to 8 in the manufacture of a
medicament for treating pathologies associated with excess cortisol formation such
as for example, obesity, diabetes, obesity related cardiovascular diseases,
35 dementia, cognition, osteoporosis and glaucoma.

ABSTRACTADAMANTYL ACETAMIDES AS HYDROXYSTEROID DEHYDROGENASE
INHIBITORS

the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein *n* represents an integer being 1 or 2; R^1 and R^2 each independently represents hydrogen C_{1-4} alkyl, NR^9R^{10} , C_{1-4} alkyloxy; or R^1 and R^2 taken together with the carbon atom with which they are attached form a C_{3-6} cycloalkyl; and where *n* is 2, either R^1 or R^2 may be absent to form an unsaturated bond; R^3 represents a C_{6-12} cycloalkyl, preferably selected from cyclo-octanyl and cyclohexyl or R^3 represents a monovalent radical having one of the following formulae



wherein said C_{6-12} cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkyloxy, halo or hydroxy; *Q* represents Het^1 or Ar^2 wherein said C_{3-8} cycloalkyl, Het^1 or Ar^2 are optionally substituted with one or where possible two or more substituents selected from halo, C_{1-4} alkyl, C_{1-4} alkyloxy, hydroxy, nitro, NR^5R^6 , C_{1-4} alkyloxy substituted with one or where possible two, three or more substituents each independently selected from hydroxycarbonyl, Het^2 and NR^7R^8 , and C_{1-4} alkyl substituted with one or where possible two or three halo substituents, preferably trifluoromethyl; R^5 and R^6 each independently represent hydrogen, C_{1-4} alkyl, or C_{1-4} alkyl substituted with phenyl; R^7 and R^8 each independently represent hydrogen or

C_{1-4} alkyl; R^9 and R^{10} each independently represent hydrogen, C_{1-4} alkyl or C_{1-4} alkyloxycarbonyl; L represents C_{1-4} alkyl; Het^1 represents a heterocycle selected from pyridinyl, thiophenyl, or 1,3-benzodioxolyl; Het^2 represents piperidinyl, pyrrolidinyl or morpholinyl; Ar^2 represents phenyl, naphthyl or indenyl.